

Marc Cohen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3732965/publications.pdf>

Version: 2024-02-01

110
papers

11,211
citations

201674

27
h-index

34986

98
g-index

112
all docs

112
docs citations

112
times ranked

10552
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients With Cardiometabolic Disease. <i>Circulation</i> , 2021, 143, 470-478.	1.6	32
2	The effect of cardiac geometry variation according to sex and race on outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention. <i>Archives of Medical Sciences Atherosclerotic Diseases</i> , 2021, 6, 152-159.	1.0	0
3	Sex Differences in Ischemic and Bleeding Outcomes in Patients With Nonâ€“ST-Segmentâ€“Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e009759.	3.9	7
4	Eccentric hypertrophy predicts adverse events in patients undergoing percutaneous coronary intervention for acute coronary syndrome. <i>Archives of Medical Sciences Atherosclerotic Diseases</i> , 2021, 6, 21-27.	1.0	3
5	Genetic Risk Score to Identify Risk of Venous Thromboembolism in Patients With Cardiometabolic Disease. <i>Circulation Genomic and Precision Medicine</i> , 2021, 14, e003006.	3.6	6
6	Predictors, Type, and Impact of Bleeding on the Net Clinical Benefit of Longâ€“Term Ticagrelor in Stable Patients With Prior Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2021, 10, e017008.	3.7	17
7	Prevalence, clinical determinants and prognostic implications of coronary procedural complications of percutaneous coronary intervention in non-ST-segment elevation myocardial infarction: Insights from the contemporary multinational TAO trial. <i>Archives of Cardiovascular Diseases</i> , 2021, 114, 187-196.	1.6	5
8	Treatment-Dose LMWH versus Prophylactic/Intermediate Dose Heparins in High-Risk COVID-19 Inpatients: Rationale and Design of the HEP-COVID Trial. <i>Thrombosis and Haemostasis</i> , 2021, 121, 1684-1695.	3.4	7
9	405 The Effect of a Patient Survey in the Evaluation of Obstructive Sleep Apnea in a High Risk Cardiology Outpatient Population. <i>Sleep</i> , 2021, 44, A161-A161.	1.1	0
10	STEMI in the Age of COVID: Unmasking Our Weaknesses. Is It the Virus That Matters?. <i>Cardiovascular Revascularization Medicine</i> , 2021, 30, 38-39.	0.8	0
11	Temporal Trends, Predictors, and Outcomes of Acute Ischemic Stroke in Acute Myocardial Infarction in the United States. <i>Journal of the American Heart Association</i> , 2021, 10, e017693.	3.7	19
12	Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19. <i>JAMA Internal Medicine</i> , 2021, 181, 1612.	5.1	326
13	Implications of Misclassification of Type 2 Myocardial Infarction on Clinical Outcomes. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 176-179.	0.8	18
14	Defining and managing patients with nonâ€“STâ€“elevation myocardial infarction: Sorting through type 1 vs other types. <i>Clinical Cardiology</i> , 2020, 43, 242-250.	1.8	18
15	Contemporary NSTEMI management: the role of the hospitalist. <i>Hospital Practice (1995)</i> , 2020, 48, 1-11.	1.0	9
16	The Utility of Echocardiography for Non-ST-Segment Elevation Myocardial Infarction: A Retrospective Study. <i>Journal of Diagnostic Medical Sonography</i> , 2020, 36, 121-129.	0.3	0
17	ST-elevation myocardial infarction in a young patient with anomalous right coronary artery and COVID-19 pneumonia. <i>European Heart Journal - Case Reports</i> , 2020, 4, 1-2.	0.6	1
18	Clinical Application of High-Sensitivity Troponin Testing in the Atherosclerotic Cardiovascular Disease Framework of the Current Cholesterol Guidelines. <i>JAMA Cardiology</i> , 2020, 5, 1255.	6.1	27

#	ARTICLE	IF	CITATIONS
19	Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Thrombosis: Phlegmasia Cerulea Dolens Presenting with Venous Gangrene in a Child. <i>Journal of Pediatrics</i> , 2020, 226, 281-284.e1.	1.8	20
20	DAPT Duration: When Less Is More. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 1507-1508.	0.8	0
21	Coronavirus disease 19 in minority populations of Newark, New Jersey. <i>International Journal for Equity in Health</i> , 2020, 19, 93.	3.5	51
22	Emergent TandemHeart-ECMO for acute severe mitral regurgitation with cardiogenic shock and hypoxaemia: a case series. <i>European Heart Journal - Case Reports</i> , 2020, 4, 1-6.	0.6	15
23	Prioritizing elective cardiovascular procedures during the COVID-19 pandemic: The cardiovascular medically necessary, time-sensitive procedure scorecard. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, E602-E607.	1.7	6
24	Safety and efficacy of antiplatelet regimens after percutaneous coronary intervention using drug eluting stents: A network meta-analysis of randomized controlled trials. <i>Progress in Cardiovascular Diseases</i> , 2020, 63, 243-248.	3.1	7
25	Effects of Prone Ventilation on Oxygenation, Inflammation, and Lung Infiltrates in COVID-19 Related Acute Respiratory Distress Syndrome: A Retrospective Cohort Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 4129.	2.4	16
26	Residual Shunt After Patent Foramen Ovale Closure and Long-Term Stroke Recurrence. <i>Annals of Internal Medicine</i> , 2020, 173, 945.	3.9	1
27	Recurrent Stroke Reduction with Patent Foramen Ovale Closure versus Medical Therapy Based on Patent Foramen Ovale Characteristics: A Meta-Analysis of Randomized Controlled Trials. <i>Cardiology</i> , 2019, 144, 40-49.	1.4	14
28	Association of International Normalized Ratio Stability and Bleeding Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007124.	3.9	11
29	Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 200-206.	3.0	25
30	Percutaneous transaxillary approach for peripheral endovascular interventions. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 94, 243-248.	1.7	8
31	Size of Anterior Wall Acute Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention in United States Versus Europe/Australia Versus India (from the CRISP-AMI Randomized) <i>Tj ETQq1 1 0.784314 rggBT /Ove</i>	1.7	8
32	Novel Oral Anticoagulant Based Versus Vitamin K Antagonist Based Double Therapy Among Stented Patients With Atrial Fibrillation. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e008160.	3.9	1
33	Cost Implications of Anticoagulation Strategies After Percutaneous Coronary Intervention Among Patients With Atrial Fibrillation (A PIONEER-AF PCI Analysis). <i>American Journal of Cardiology</i> , 2019, 123, 355-360.	1.6	6
34	Biliary Disease in Immunocompromised Patients: a Single-Center Retrospective Analysis. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 1589-1592.	1.7	3
35	Routine Invasive Versus Selective Invasive Strategy in Elderly Patients Older Than 75 Years With Non-ST-Segment Elevation Acute Coronary Syndrome: A Systematic Review and Meta-Analysis. <i>Mayo Clinic Proceedings</i> , 2018, 93, 436-444.	3.0	24
36	Effect of Procedure and Coronary Lesion Characteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 626-634.	2.9	25

#	ARTICLE	IF	CITATIONS
37	Jetstream atherectomy and balloon angioplasty with distal embolic protection for Angio-Seal-related vascular access complications. <i>Cardiovascular Intervention and Therapeutics</i> , 2018, 33, 264-269.	2.3	0
38	Differential responses to larger volume intra-aortic balloon counterpulsation: Hemodynamic and clinical outcomes. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 92, 703-710.	1.7	19
39	Frequency, Predictors, and Impact of Combined Antiplatelet Therapy on Venous Thromboembolism in Patients With Symptomatic Atherosclerosis. <i>Circulation</i> , 2018, 137, 684-692.	1.6	22
40	Usefulness of Rivaroxaban for Secondary Prevention of Acute Coronary Syndrome in Patients With History of Congestive Heart Failure (from the ATLAS-ACS-2 TIMI-51 Trial). <i>American Journal of Cardiology</i> , 2018, 122, 1896-1901.	1.6	17
41	Total bleeding with rivaroxaban versus warfarin in patients with atrial fibrillation receiving antiplatelet therapy after percutaneous coronary intervention. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 46, 346-350.	2.1	10
42	Activated Clotting Time to Guide Heparin Dosing in Non-ST-Segment Elevation Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention and Treated With IIb/IIIa Inhibitors. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e006084.	3.9	7
43	Safety and efficacy of non-vitamin K oral anticoagulant for atrial fibrillation patients after percutaneous coronary intervention: A bivariate analysis of the PIONEER AF-PCI and RE-DUAL PCI trial. <i>American Heart Journal</i> , 2018, 203, 17-24.	2.7	10
44	Takeoff orientation of the major aortic arch branches irrespective of arch type: Ramifications for brachiocephalic interventions including carotid stenting. <i>SAGE Open Medicine</i> , 2018, 6, 205031211877671.	1.8	2
45	Intravenous Enoxaparin Versus Unfractionated Heparin in Elderly Patients Undergoing Primary Percutaneous Coronary Intervention. <i>Angiology</i> , 2017, 68, 29-39.	1.8	10
46	A single center tertiary care experience utilizing the large volume mega 50cc intra-aortic balloon counterpulsation in contemporary clinical practice. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 90, E63-E72.	1.7	11
47	Meta-Analysis of Randomized Controlled Trials of Percutaneous Coronary Intervention With Drug-Eluting Stents Versus Coronary Artery Bypass Grafting in Left Main Coronary Artery Disease. <i>American Journal of Cardiology</i> , 2017, 119, 1942-1948.	1.6	21
48	Timing of Angiography and Outcomes in High-Risk Patients With Non-ST-Segment Elevation Myocardial Infarction Managed Invasively. <i>Circulation</i> , 2017, 136, 1895-1907.	1.6	29
49	Cost-Effectiveness of Long-Term Ticagrelor in Patients With Prior Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2017, 70, 527-538.	2.8	23
50	Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy. <i>Circulation</i> , 2017, 135, 323-333.	1.6	86
51	Cardiac troponin and outcome in decompensated heart failure with preserved ejection fraction. <i>Cardiovascular Diagnosis and Therapy</i> , 2017, 7, 359-366.	1.7	14
52	Coronary artery bypass grafting versus percutaneous coronary intervention in complex coronary artery disease: looking beyond clinical end-points. <i>Annals of Translational Medicine</i> , 2017, 5, 491-491.	1.7	0
53	Impact of Tricuspid Valve Regurgitation on Early Outcomes after Transcatheter Aortic Valve Replacement. <i>Journal of Heart Valve Disease</i> , 2017, 26, 380-385.	0.5	5
54	Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trial. <i>European Heart Journal</i> , 2016, 37, ehv482.	2.2	70

#	ARTICLE	IF	CITATIONS
55	Poorly recognized age-related downward deviation of the inguinal ligament. <i>SAGE Open Medicine</i> , 2016, 4, 205031211667556.	1.8	1
56	CT Angiography Analysis of Axillary Artery Diameter versus Common Femoral Artery Diameter: Implications for Axillary Approach for Transcatheter Aortic Valve Replacement in Patients with Hostile Aortoiliac Segment and Advanced Lung Disease. <i>International Journal of Vascular Medicine</i> , 2016, 2016, 1-5.	1.0	28
57	Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1661-1671.	2.8	69
58	Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2719-2728.	2.8	303
59	Reduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUS-TIMI 54. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2732-2740.	2.8	179
60	Efficacy and Safety of Proton-Pump Inhibitors in High-Risk Cardiovascular Subsets of the COGENT Trial. <i>American Journal of Medicine</i> , 2016, 129, 1002-1005.	1.5	32
61	Quantitative increase in frailty is associated with diminished survival after transcatheter aortic valve replacement. <i>American Heart Journal</i> , 2016, 182, 146-154.	2.7	40
62	Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction. <i>Circulation</i> , 2016, 134, 861-871.	1.6	40
63	Impact of Non-Infarct-Related Artery Disease on Infarct Size and Outcomes (from the CRISP-AMI Trial). <i>American Journal of Medicine</i> , 2016, 129, 1307-1315.	1.5	5
64	Ubiquitous Nature of Distal Athero/Thromboembolic Events during Lower Extremity Atherectomy Procedures Involving the Superficial Femoral Artery. <i>International Journal of Angiology</i> , 2016, 25, 252-257.	0.6	4
65	Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. <i>New England Journal of Medicine</i> , 2016, 375, 2423-2434.	27.0	1,265
66	Long-term Tolerability of Ticagrelor for the Secondary Prevention of Major Adverse Cardiovascular Events. <i>JAMA Cardiology</i> , 2016, 1, 425.	6.1	88
67	Long-term outcomes in high-risk patients with non-ST-segment elevation myocardial infarction. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 41, 464-474.	2.1	18
68	Clinical characteristics and outcomes after unplanned intraaortic balloon counterpulsation in the Counterpulsation to Reduce Infarct Size Pre-PCI Acute Myocardial Infarction trial. <i>American Heart Journal</i> , 2016, 174, 7-13.	2.7	3
69	Acute left ventricular dysfunction complicating pregnancy on ECMO: Tri-iodothyronine to the rescue with real time transesophageal echocardiography. <i>Journal of Cardiology Cases</i> , 2016, 13, 33-36.	0.5	2
70	Platelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 Trial. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1145-1154.	2.8	108
71	Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y ₁₂ inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54. <i>European Heart Journal</i> , 2016, 37, 1133-1142.	2.2	138
72	Aortico-Left Atrial Fistula: A Rare Complication of Bioprosthetic Aortic Valve Endocarditis Secondary to <i>Enterococcus faecalis</i> . <i>Case Reports in Cardiology</i> , 2015, 2015, 1-4.	0.2	9

#	ARTICLE	IF	CITATIONS
73	An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin k antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI). <i>American Heart Journal</i> , 2015, 169, 472-478.e5.	2.7	140
74	Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction. <i>New England Journal of Medicine</i> , 2015, 372, 1791-1800.	27.0	1,585
75	Incidence and consequence of major bleeding in primary percutaneous intervention for ST-elevation myocardial infarction in the era of radial access: an analysis of the international randomized Acute myocardial infarction Treated with primary angioplasty and intravenous enoxaparin Or unfractionated heparin to Lower ischemic and bleeding events at short- and Long-term follow-up trial. <i>American Heart Journal</i> , 2015, 170, 778-786.	2.7	9
76	Where are we with vascular closure devices after percutaneous arteriotomy?. <i>Journal of Invasive Cardiology</i> , 2015, 27, 136-7.	0.4	0
77	Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin—Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial. <i>American Heart Journal</i> , 2014, 167, 437-444.e5.	2.7	89
78	The “Dual” Pathway Strategy after Acute Coronary Syndrome: Rivaroxaban and Antiplatelet Agents in the ATLAS ACS 2—TIMI 51 Trial. <i>Cardiovascular Therapeutics</i> , 2014, 32, 224-232.	2.5	10
79	Rivaroxaban in Patients with a Recent Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , 2012, 366, 9-19.	27.0	1,681
80	US Food and Drug Administration approval of generic versions of complex biologics: implications for the practicing physician using low molecular weight heparins. <i>Journal of Thrombosis and Thrombolysis</i> , 2012, 33, 230-238.	2.1	10
81	Improving Long-Term ACS Management: Is There a Role for the New Antiplatelets?. <i>Journal of Interventional Cardiology</i> , 2012, 25, 425-432.	1.2	4
82	The Management of Patients with Atrial Fibrillation and Dronedarone’s Place in Therapy. <i>Advances in Therapy</i> , 2011, 28, 1059-1077.	2.9	6
83	Enoxaparin 0.3 mg/kg IV supplement for patients transitioning to PCI after subcutaneous enoxaparin therapy for NSTEMI ACS: A subgroup analysis from the SYNERGY trial. <i>Catheterization and Cardiovascular Interventions</i> , 2010, 75, 928-935.	1.7	15
84	Therapy for ST-Segment Elevation Myocardial Infarction Patients Who Present Late or Are Ineligible for Reperfusion Therapy. <i>Journal of the American College of Cardiology</i> , 2010, 55, 1895-1906.	2.8	47
85	Clopidogrel with or without Omeprazole in Coronary Artery Disease. <i>New England Journal of Medicine</i> , 2010, 363, 1909-1917.	27.0	1,019
86	The Thrombin Hypothesis in ACS: A Disappointing Disconnect between Bench Data and Bedside Clinical Trials. <i>American Journal of Medicine</i> , 2010, 123, 103-110.	1.5	5
87	Antiplatelet therapy in percutaneous coronary intervention: A critical review of the 2007 AHA/ACC/SCAI guidelines and beyond. <i>Catheterization and Cardiovascular Interventions</i> , 2009, 74, 579-597.	1.7	26
88	Oral Antiplatelet Therapy for Acute and Chronic Management of NSTEMI ACS: Residual Ischemic Risk and Opportunities for Improvement. <i>Cardiovascular Drugs and Therapy</i> , 2009, 23, 489-499.	2.6	6
89	Re-evaluating risk factors for periprocedural complications during percutaneous coronary intervention in patients with unstable angina/non-ST-elevation myocardial infarction: who may benefit from more intensive antiplatelet therapy?. <i>Current Opinion in Cardiology</i> , 2009, 24, 88-94.	1.8	6
90	Expanding the recognition and assessment of bleeding events associated with antiplatelet therapy in primary care. <i>Mayo Clinic Proceedings</i> , 2009, 84, 149-60.	3.0	5

#	ARTICLE	IF	CITATIONS
91	High-risk Acute Coronary Syndrome Patients with Non-ST-Elevation Myocardial Infarction: Definition and Treatment. <i>Cardiovascular Drugs and Therapy</i> , 2008, 22, 407-418.	2.6	5
92	Bleeding after antithrombotic therapy in patients with acute ischemic heart disease. <i>Journal of Thrombosis and Thrombolysis</i> , 2008, 26, 175-182.	2.1	8
93	Pathophysiology and Disease Progression of Atrial Fibrillation: Importance of Achieving and Maintaining Sinus Rhythm. <i>Journal of Cardiovascular Electrophysiology</i> , 2008, 19, 885-890.	1.7	27
94	Treatment Strategies in Non-ST-Elevation Acute Coronary Syndromes in Patients Undergoing Percutaneous Coronary Intervention: An Evidence-Based Review of Clinical Trial Results and Treatment Guidelines: Report on a Roundtable Discussion. <i>Journal of Interventional Cardiology</i> , 2008, 21, 283-299.	1.2	2
95	The use of adjunctive anticoagulants in patients with acute coronary syndrome transitioning to percutaneous coronary intervention. <i>American Journal of Emergency Medicine</i> , 2008, 26, 932-941.	1.6	1
96	Randomized, Double-Blind, Dose-Ranging Study of Otamixaban, a Novel, Parenteral, Short-Acting Direct Factor Xa Inhibitor, in Percutaneous Coronary Intervention. <i>Circulation</i> , 2007, 115, 2642-2651.	1.6	96
97	The Role of Serial Testing for Heparin/PF4 Antibodies in Evolving HIT: A Unique Phenomenon of Delayed Seroconversion with Thrombosis.. <i>Blood</i> , 2007, 110, 1309-1309.	1.4	0
98	Pharmacoinvasive management of acute coronary syndrome: incorporating the 2007 ACC/AHA guidelines: the CATH (cardiac catheterization and antithrombotic therapy in the hospital) Clinical Consensus Panel Report-III. <i>Journal of Invasive Cardiology</i> , 2007, 19, 525-38; quiz 539-40.	0.4	11
99	A Subgroup Analysis of the Impact of Prerandomization Antithrombin Therapy on Outcomes in the SYNERGY Trial. <i>Journal of the American College of Cardiology</i> , 2006, 48, 1346-1354.	2.8	79
100	At six months, enoxaparin is more effective than tinzaparin for people with non ST-segment elevation acute coronary syndromes. <i>Evidence-based Cardiovascular Medicine</i> , 2006, 10, 30-31.	0.0	0
101	The Role of Gender and Other Factors as Predictors of Not Receiving Reperfusion Therapy and of Outcome in ST-Segment Elevation Myocardial Infarction. <i>Journal of Thrombosis and Thrombolysis</i> , 2005, 19, 155-161.	2.1	26
102	The evolution of thrombolytic therapy and adjunctive antithrombotic regimens in acute ST-segment elevation myocardial infarction. <i>American Journal of Emergency Medicine</i> , 2004, 22, 14-23.	1.6	9
103	The Influence of Prior Oral Anticoagulation Therapy on the Anticoagulant Effect of Low Molecular Weight Heparin.. <i>Blood</i> , 2004, 104, 4080-4080.	1.4	9
104	The role of low-molecular-weight heparin in the management of acute coronary syndromes. <i>Journal of the American College of Cardiology</i> , 2003, 41, S55-S61.	2.8	27
105	The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI). <i>Journal of the American College of Cardiology</i> , 2003, 42, 1348-1356.	2.8	80
106	Prospective Evaluation of Clinical Outcomes After Acute ST-Elevation Myocardial Infarction in Patients Who Are Ineligible for Reperfusion Therapy: Preliminary Results From the TETAMI Registry and Randomized Trial. <i>Circulation</i> , 2003, 108, 1411-21.	1.6	41
107	Antiplatelet therapy versus other antithrombotic strategies. , 2001, , 367-385.		0
108	The TIMI Risk Score for Unstable Angina/Non-ST Elevation MI. <i>JAMA - Journal of the American Medical Association</i> , 2000, 284, 835.	7.4	2,704

#	ARTICLE	IF	CITATIONS
109	Pathogenesis of Coronary Occlusion. Hospital Practice (1995), 1988, 23, 87-99.	1.0	3
110	Antiplatelet Effects of Thrombin Inhibitors and Fibrinolytic Agents. , 0, , 125-142.		0